Visit Competitors to Danuglipron Danuglipron, though not yet approved by the FDA, is part of a new class of weight loss drugs called GLP-1 receptor agonists
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Non-surgical skin tightening treatments are designed for patients with mild to moderate skin laxity who want improvement without incisions, general anesthesia, or a longer recovery
"As use of this medication is extended and expanded for weight loss and other health advocacy, there is an opportunity to do much more, including product development, packaging, online and in-store merchandising, education, and promotion." Opportunities include: Merchandise dietary and nutritional support items near the pharmacy in drug and grocery, improving the shopping experience for consumers taking GLP-1s Understand that 91% of Millennials, 90% of Gen Z, and 64% of Gen X on GLP-1 medications are interested in packaged foods that support their weight loss goals, and they want messaging called out on the package Meet consumers where they are with product and health information, amplifying digital commerce programming Advance opportunities on retailer apps and websites to support these shoppers Acosta Group's "GLP-1 & The Weight Loss Revolution Shopper Insights Study" was conducted Feb
